X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D | 2024-03-21 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $145.06 | -5,000 | 7,507 | -40% | -$725,320 | |||||
D | 2024-03-14 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $139.38 | -75,000 | 40,778 | -65% | -$10,453,418 | |||||
D | 2024-03-14 | NBIX | Morrow George J | Dir | S - Sale+OE | $139.42 | -40,000 | 0 | -100% | -$5,576,710 | |||||
D | 2024-03-13 | NBIX | Pops Richard F | Dir | S - Sale+OE | $140.33 | -23,200 | 29,512 | -44% | -$3,255,621 | |||||
D | 2024-03-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.14 | -3,000 | 7,507 | -29% | -$420,419 | |||||
DM | 2024-03-08 | NBIX | Pops Richard F | Dir | S - Sale+OE | $140.04 | -1,800 | 29,512 | -6% | -$252,078 | |||||
DM | 2024-03-08 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.03 | -2,000 | 7,507 | -21% | -$280,053 | |||||
DM | 2024-02-28 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $135.34 | -6,817 | 7,507 | -48% | -$922,632 | |||||
D | 2024-02-28 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $134.69 | -75,000 | 40,616 | -65% | -$10,101,608 | |||||
D | 2024-02-27 | NBIX | Norwalk Leslie V | Dir | S - Sale+OE | $135.67 | -8,000 | 0 | -100% | -$1,085,388 | |||||
D | 2024-02-20 | NBIX | Pops Richard F | Dir | S - Sale+OE | $132.47 | -15,000 | 29,512 | -34% | -$1,987,047 | |||||
D | 2024-02-13 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $132.96 | -1,114 | 23,716 | -4% | -$148,122 | |||||
D | 2024-02-13 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $132.94 | -1,432 | 13,128 | -10% | -$190,371 | |||||
D | 2024-02-13 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $133.00 | -1,098 | 39,740 | -3% | -$146,028 | |||||
D | 2024-02-13 | NBIX | Gorman Kevin Charles | CEO | S - Sale+OE | $133.02 | -2,832 | 514,596 | -1% | -$376,700 | |||||
D | 2024-02-13 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale+OE | $132.90 | -1,352 | 135,166 | -1% | -$179,674 | |||||
D | 2024-02-13 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $133.04 | -716 | 7,507 | -9% | -$95,253 | |||||
D | 2024-02-13 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $133.04 | -796 | 17,976 | -4% | -$105,902 | |||||
D | 2024-02-13 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale+OE | $133.07 | -1,811 | 4,895 | -27% | -$240,996 | |||||
D | 2024-02-13 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.02 | -1,098 | 40,616 | -3% | -$146,050 | |||||
D | 2024-02-13 | NBIX | Abernethy Matt | CFO | S - Sale+OE | $132.85 | -1,352 | 31,528 | -4% | -$179,612 | |||||
M | 2024-02-06 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $137.09 | -1,784 | 4,895 | -27% | -$244,564 | |||||
M | 2024-02-06 | NBIX | Cooke Julie | CHRO | S - Sale | $138.61 | -2,544 | 17,263 | -13% | -$352,612 | |||||
M | 2024-02-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $138.49 | -2,101 | 22,717 | -8% | -$290,968 | |||||
M | 2024-02-06 | NBIX | Lippoldt Darin | GC | S - Sale | $138.47 | -1,952 | 38,755 | -5% | -$270,284 | |||||
M | 2024-02-06 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $138.74 | -5,314 | 506,962 | -1% | -$737,271 | |||||
M | 2024-02-06 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $139.16 | -2,580 | 133,952 | -2% | -$359,041 | |||||
M | 2024-02-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $138.68 | -2,260 | 39,631 | -5% | -$313,419 | |||||
M | 2024-02-06 | NBIX | Abernethy Matt | CFO | S - Sale | $138.73 | -2,260 | 30,314 | -7% | -$313,530 | |||||
2024-01-31 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $140.79 | -1,457 | 20,832 | -7% | -$205,132 | ||||||
2024-01-31 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $141.94 | -126 | 11,843 | -1% | -$17,884 | ||||||
2024-01-31 | NBIX | Lippoldt Darin | GC | S - Sale | $140.65 | -1,250 | 37,005 | -3% | -$175,810 | ||||||
2024-01-31 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $140.69 | -2,707 | 502,188 | -1% | -$380,845 | ||||||
2024-01-31 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $140.70 | -1,541 | 131,635 | -1% | -$216,813 | ||||||
M | 2024-01-31 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $140.65 | -1,045 | 6,865 | -13% | -$146,975 | |||||
2024-01-31 | NBIX | Cooke Julie | CHRO | S - Sale | $141.29 | -1,740 | 17,263 | -9% | -$245,842 | ||||||
2024-01-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $140.80 | -2,096 | 4,894 | -30% | -$295,115 | ||||||
2024-01-31 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $140.78 | -1,207 | 37,601 | -3% | -$169,927 | ||||||
2024-01-31 | NBIX | Abernethy Matt | CFO | S - Sale | $140.72 | -1,283 | 28,284 | -4% | -$180,539 | ||||||
D | 2024-01-22 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $139.86 | -10,000 | 35,882 | -22% | -$1,398,553 | |||||
DM | 2024-01-08 | NBIX | Gorman Kevin Charles | CEO | S - Sale+OE | $133.02 | -167,858 | 499,754 | -25% | -$22,328,417 | |||||
D | 2024-01-02 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale+OE | $131.47 | -75,000 | 130,250 | -37% | -$9,860,194 | |||||
D | 2024-01-02 | NBIX | Rastetter William H | Dir | S - Sale+OE | $131.47 | -11,044 | 51,741 | -18% | -$1,451,927 | |||||
2023-12-22 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $126.75 | -10,000 | 19,521 | -34% | -$1,267,448 | ||||||
2023-12-22 | NBIX | Lyons Gary A | Dir | S - Sale | $130.04 | -10,000 | 193,697 | -5% | -$1,300,443 | ||||||
D | 2023-12-22 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $128.66 | -24,000 | 17,263 | -58% | -$3,087,808 | |||||
D | 2023-12-12 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $120.30 | -13,925 | 29,521 | -32% | -$1,675,240 | |||||
DM | 2023-12-07 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $120.37 | -77,679 | 29,521 | -72% | -$9,350,350 | |||||
D | 2023-12-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $120.03 | -8,396 | 29,521 | -22% | -$1,007,780 | |||||
D | 2023-12-06 | NBIX | Lippoldt Darin | GC | S - Sale+OE | $119.86 | -20,830 | 35,882 | -37% | -$2,496,648 | |||||
D | 2023-12-01 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $116.77 | -5,000 | 203,697 | -2% | -$583,837 | |||||
2023-11-29 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $113.57 | -2,331 | 11,732 | -17% | -$264,733 | ||||||
2023-11-27 | NBIX | Lippoldt Darin | GC | S - Sale | $112.27 | -10,919 | 35,882 | -23% | -$1,225,911 | ||||||
2023-10-02 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $112.68 | -1,437 | 4,894 | -23% | -$161,921 | ||||||
D | 2023-09-12 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $115.02 | -5,000 | 203,697 | -2% | -$575,120 | |||||
D | 2023-09-01 | NBIX | Lyons Gary A | Dir | S - Sale+OE | $110.06 | -5,000 | 203,697 | -2% | -$550,316 | |||||
2023-09-01 | NBIX | Cooke Julie | CHRO | S - Sale | $110.93 | -824 | 17,263 | -5% | -$91,406 | ||||||
2023-08-30 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $107.60 | -2,733 | 3,460 | -44% | -$294,058 | ||||||
2023-08-28 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $107.52 | -1,431 | 5,931 | -19% | -$153,861 | ||||||
2023-08-21 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $107.38 | -3,198 | 29,521 | -10% | -$343,388 | ||||||
2023-08-21 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $107.37 | -3,198 | 9,638 | -25% | -$343,368 | ||||||
2023-08-21 | NBIX | Lippoldt Darin | GC | S - Sale | $107.39 | -2,132 | 46,991 | -4% | -$228,951 | ||||||
2023-08-21 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $107.40 | -9,328 | 499,754 | -2% | -$1,001,816 | ||||||
2023-08-21 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $107.41 | -2,132 | 130,250 | -2% | -$228,993 | ||||||
2023-08-21 | NBIX | Delaet Ingrid | Chief Regulatory Officer | S - Sale | $107.42 | -1,404 | 4,645 | -23% | -$150,820 | ||||||
2023-08-21 | NBIX | Cooke Julie | CHRO | S - Sale | $107.41 | -2,132 | 18,087 | -11% | -$228,991 | ||||||
2023-08-21 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $107.41 | -1,600 | 6,193 | -21% | -$171,862 | ||||||
2023-08-21 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $107.40 | -1,600 | 36,436 | -4% | -$171,836 | ||||||
2023-08-21 | NBIX | Abernethy Matt | CFO | S - Sale | $107.39 | -2,132 | 27,131 | -7% | -$228,958 | ||||||
D | 2023-05-01 | NBIX | Rastetter William H | Dir | S - Sale+OE | $101.43 | -4,300 | 42,785 | -9% | -$436,135 | |||||
2023-05-01 | NBIX | Cooke Julie | CHRO | S - Sale | $103.89 | -11,397 | 16,169 | -41% | -$1,184,049 | ||||||
2023-04-25 | NBIX | Cooke Julie | CHRO | S - Sale | $103.82 | -100 | 27,561 | 0% | -$10,382 | ||||||
2023-04-24 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $103.48 | -14,400 | 26,644 | -35% | -$1,490,059 | ||||||
DM | 2023-04-19 | NBIX | Rastetter William H | Dir | S - Sale+OE | $105.03 | -6,937 | 39,460 | -15% | -$728,605 | |||||
M | 2023-02-06 | NBIX | Cooke Julie | CHRO | S - Sale | $102.77 | -17,079 | 27,424 | -38% | -$1,755,121 | |||||
M | 2023-02-06 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $102.74 | -16,525 | 41,015 | -29% | -$1,697,707 | |||||
2023-02-07 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $102.30 | -4,508 | 6,525 | -41% | -$461,166 | ||||||
M | 2023-02-06 | NBIX | Lloyd-Smith Malcolm | Chief Integration Officer | S - Sale | $102.64 | -15,318 | 42,337 | -27% | -$1,572,197 | |||||
M | 2023-02-06 | NBIX | Lippoldt Darin | GC | S - Sale | $102.71 | -16,275 | 44,973 | -27% | -$1,671,637 | |||||
M | 2023-02-06 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $102.90 | -29,044 | 491,365 | -6% | -$2,988,758 | |||||
M | 2023-02-06 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $102.80 | -17,004 | 128,096 | -12% | -$1,747,920 | |||||
M | 2023-02-06 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $102.49 | -25,238 | 4,755 | -84% | -$2,586,741 | |||||
M | 2023-02-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $102.70 | -19,650 | 34,381 | -36% | -$2,018,105 | |||||
M | 2023-02-06 | NBIX | Abernethy Matt | CFO | S - Sale | $102.61 | -28,588 | 25,213 | -53% | -$2,933,470 | |||||
2023-01-31 | NBIX | Roberts Eiry | Chief Medical Officer | S - Sale | $109.99 | -1,457 | 26,171 | -5% | -$160,254 | ||||||
2023-01-31 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $108.48 | -126 | 2,477 | -5% | -$13,668 | ||||||
2023-01-31 | NBIX | Lloyd-Smith Malcolm | Chief Integration Officer | S - Sale | $110.02 | -1,666 | 28,582 | -6% | -$183,290 | ||||||
2023-01-31 | NBIX | Lippoldt Darin | GC | S - Sale | $109.97 | -1,250 | 30,357 | -4% | -$137,464 | ||||||
2023-01-31 | NBIX | Gorman Kevin Charles | CEO | S - Sale | $110.08 | -2,707 | 465,278 | -1% | -$297,997 | ||||||
2023-01-31 | NBIX | Gano Kyle | Chief Business Development Off | S - Sale | $109.99 | -1,541 | 112,820 | -1% | -$169,486 | ||||||
2023-01-31 | NBIX | Cooke Julie | CHRO | S - Sale | $108.48 | -916 | 15,926 | -5% | -$99,368 | ||||||
2023-01-31 | NBIX | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $109.92 | -1,104 | 3,911 | -22% | -$121,349 | ||||||
2023-01-31 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale | $109.95 | -1,207 | 16,729 | -7% | -$132,710 | ||||||
2023-01-31 | NBIX | Abernethy Matt | CFO | S - Sale | $109.98 | -1,283 | 21,357 | -6% | -$141,108 | ||||||
D | 2023-01-06 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.00 | -400 | 15,643 | -2% | -$50,000 | |||||
D | 2023-01-03 | NBIX | Sherwin Stephen A | Dir | S - Sale+OE | $118.86 | -30,000 | 25,055 | -54% | -$3,565,728 | |||||
D | 2023-01-03 | NBIX | Pops Richard F | Dir | S - Sale+OE | $119.20 | -15,000 | 29,512 | -34% | -$1,788,045 | |||||
D | 2022-11-30 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.90 | -50,000 | 15,643 | -76% | -$6,295,085 | |||||
2022-11-29 | NBIX | Onyia Jude | Chief Scientific Officer | S - Sale | $121.91 | -2,331 | 2,366 | -50% | -$284,160 | ||||||
DM | 2022-11-08 | NBIX | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $125.33 | -24,693 | 15,643 | -61% | -$3,094,856 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |